GlaxoSmithKline's Nucala scores Dupixent-hunting trial win in nasal polyps

6th April 2020 Uncategorised 0

GlaxoSmithKline’s IL-5 inhibitor Nucala is facing stiff competition from a suite of asthma competitors. But in nasal polyps—an indication where no IL-5 has gone before—Nucala is hoping it can take the fight directly to Sanofi and Regeneron’s blockbuster Dupixent.

More: GlaxoSmithKline's Nucala scores Dupixent-hunting trial win in nasal polyps
Source: fierce